Fig. 2: Kaplan-Meier analysis of molecular relapse–free survival (MRFS) in the ENDURE trial. | Leukemia

Fig. 2: Kaplan-Meier analysis of molecular relapse–free survival (MRFS) in the ENDURE trial.

From: Randomized phase 3 trial of Ropeginterferon alfa-2b versus surveillance after tyrosine kinase inhibitor discontinuation in chronic myeloid leukemia (ENDURE/CML-IX)

Fig. 2: Kaplan-Meier analysis of molecular relapse–free survival (MRFS) in the ENDURE trial.

MRFS probabilities are shown for patients with CML who discontinued TKI therapy after one month and were randomized to receive either ropeginterferon alfa-2b (ropeg-IFN) maintenance for 15 months or surveillance. At months 7, 13, and 25 after randomization (corresponding to 6, 12, and 24 months after TKI discontinuation), MRFS probabilities were 73%, 64%, and 56% in the ropeg-IFN arm and 67%, 60%, and 59% in the surveillance arm, respectively. Numbers below the graph indicate patients at risk at each time point. CI confidence interval, HR hazard ratio.

Back to article page